<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060706</url>
  </required_header>
  <id_info>
    <org_study_id>Hamlet.rt</org_study_id>
    <nct_id>NCT04060706</nct_id>
  </id_info>
  <brief_title>Heuristics, Algorithms and Machine Learning: Evaluation &amp; Testing in Radiation Therapy</brief_title>
  <acronym>Hamlet rt</acronym>
  <official_title>Hamlet-RT: Heuristics, Algorithms and Machine Learning: Evaluation &amp; Testing in Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CCTU- Cancer Theme</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Microsoft Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Hamlet.rt study is a prospective data collection and patient questionnaire study for
      patients undergoing image-guided radiotherapy with curative intent.

      The aim of the study is to use novel machine learning and mathematical techniques to build a
      model that can predict the risk of significant side effects from radiotherapy treatment for
      an individual patient: using calculations of normal tissue dose from radiotherapy treatment
      planning and patient baseline characteristics derived from image and non-image data,
      continuously updated as the patient is reviewed both during and after treatment.

      A secondary goal of the project is to facilitate research in machine learning and medical
      image processing for radiation therapy through the creation of a discoverable and shared data
      resource for research use.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Machine Learning Modelling</measure>
    <time_frame>8 years from FPFV</time_frame>
    <description>Characterise machine learning models for the four disease sites. Developing machine learning algorithms for autosegmentation of normal tissue anatomy, and to extend machine learning algorithms to identify and segment normal tissue structures in cone beam CT images, and to utilise the ML segmentations to evaluate image signatures correlated with treatment toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive Modelling</measure>
    <time_frame>8 years from FPFV</time_frame>
    <description>Predict performance matches with published techniques. Combining the machine learning models in outcome 1, with pre-treatment assessment data and on-treatment quantitative assessments in outcome 3 for the construction and evaluation of a predictive mathematical model</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Toxicity Evaluation</measure>
    <time_frame>8 years from FPFV</time_frame>
    <description>Evaluation of the clinical toxicity experienced by each patient up to 5 years post radiotherapy to inform the predictive models in outcome 2</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate Cancer</arm_group_label>
    <description>Adults suitable for radical image-guided radiotherapy for their Prostate cancer, approximately 170 patients Components from RTOG, LENT SOM(A), RMH symptom scale and UCLA PCI (prostate cancer index) questionnaires will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head &amp; Neck Cancer</arm_group_label>
    <description>Adults suitable for radical image-guided radiotherapy for their Head &amp; Neck cancer, approximately 140 patients. Components from CTCAE v3, LENT SOM(A), EORTC QLQ H+N35 &amp; Modified xerostomia questionnaires will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central Nervous System Tumours</arm_group_label>
    <description>Adults suitable for radical image-guided radiotherapy for their CNS tumour, as many patients recruited as possible. Components from RTOG, LENT SOM(A), Folstein mini mental state examination &amp; Generalised activites of daily living scale (G-ADL) questionnaires will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung Cancer</arm_group_label>
    <description>Adults suitable for radical image-guided radiotherapy for their Lung cancer, as many patients recruited as possible. Components from RTOG &amp; LENT SOM(A) questionnaires will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radical Image-Guided Radiotherapy</intervention_name>
    <description>Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy</description>
    <arm_group_label>Central Nervous System Tumours</arm_group_label>
    <arm_group_label>Head &amp; Neck Cancer</arm_group_label>
    <arm_group_label>Lung Cancer</arm_group_label>
    <arm_group_label>Prostate Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults suitable for radical image-guided radiotherapy with Prostate, Head &amp; Neck, Brain, or
        Lung Cancer. The variation in conditions is based on the requirements of Machine Learning
        algorithms requiring high levels of clinical applicability, which depends on the quality
        and quantity of the input data available. The input data set therefore should adequately
        encompass the variation in anatomy encountered in the population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study

          -  Male or Female

          -  Aged 18 years or older

          -  Diagnosed with primary prostate cancer, head and neck cancer, lung cancer, or brain
             tumour

          -  Treated with curative intent

          -  Suitable for radical image guided radiotherapy

          -  WHO ECOG performance status 0 or 1

          -  Expected survival of 18 months or more

        Exclusion Criteria:

          -  Participant is not willing or able to complete the protocol-stated requirements of the
             study, e.g. accessing &amp; completing web-based long-term follow-up questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Raj Dr. Jena</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust &amp; the University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Skells</last_name>
    <phone>01223 349707</phone>
    <phone_ext>349707</phone_ext>
    <email>richard.skells@addenbrookes.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CCTU Cancer</last_name>
    <phone>01223 216038</phone>
    <phone_ext>216038</phone_ext>
    <email>cctuc@addenbrookes.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Amy Bates</last_name>
      <phone>01223 256296</phone>
      <phone_ext>256296</phone_ext>
      <email>amy.bates@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Raj Dr. Jena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>CCTU- Cancer Theme</investigator_full_name>
    <investigator_title>Dr. Raj Jena, Chief Investigator</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Image-guided</keyword>
  <keyword>Head &amp; Neck</keyword>
  <keyword>Brain</keyword>
  <keyword>Lung</keyword>
  <keyword>Prostate</keyword>
  <keyword>Adults</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

